Based on the biote Corp stock forecast from 3 analysts, the average analyst target price for biote Corp is USD 10.33 over the next 12 months. biote Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of biote Corp is Bullish , which is based on 9 positive signals and 3 negative signals. At the last closing, biote Corp’s stock price was USD 5.54. biote Corp’s stock price has changed by -9.18% over the past week, -13.03% over the past month and +22.30% over the last year.
No recent analyst target price found for biote Corp
No recent average analyst rating found for biote Corp
Company Overview biote Corp
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas. Read Less
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offer...Read More
Frequently Asked Questions About biote Corp (BTMD) Stock
Based on ratings from 3 analysts biote Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on BTMD's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for BTMD is USD 10.33 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 8.
BTMD stock's Price/Earning ratio is 18.83.
Our analysis grades BTMD stock's Price / Earning ratio at C-. This means that BTMD stock's Price/Earning ratio is above 29% of the stocks in the Medical Care Facilities sector in the NSD exchange.
Based on this BTMD may be undervalued for its sector.
The last closing price of BTMD's stock was USD 5.54.
The most recent market capitalization for BTMD is USD 0.30B.
Based on targets from 3 analysts, the average taret price for BTMD is projected at USD 10.33 over the next 12 months.
This means that BTMD's stock price may go up by +86.52% over the next 12 months.
We can't find any ETFs which contains biote Corp's stock.
As per our most recent records biote Corp has 194 Employees.
biote Corp's registered address is 1875 W. Walnut Hill Ln #100, Irving, TX, United States, 75038.
You can get more information about it from biote Corp's website at https://biote.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About biote Corp (BTMD) Stock
Based on ratings from 3 analysts biote Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on BTMD's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for BTMD is USD 10.33 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 8.
BTMD stock's Price/Earning ratio is 18.83.
Our analysis grades BTMD stock's Price / Earning ratio at C-. This means that BTMD stock's Price/Earning ratio is above 29% of the stocks in the Medical Care Facilities sector in the NSD exchange.
Based on this BTMD may be undervalued for its sector.
The last closing price of BTMD's stock was USD 5.54.
The most recent market capitalization for BTMD is USD 0.30B.
Based on targets from 3 analysts, the average taret price for BTMD is projected at USD 10.33 over the next 12 months.
This means that BTMD's stock price may go up by +86.52% over the next 12 months.
We can't find any ETFs which contains biote Corp's stock.
As per our most recent records biote Corp has 194 Employees.
biote Corp's registered address is 1875 W. Walnut Hill Ln #100, Irving, TX, United States, 75038.
You can get more information about it from biote Corp's website at https://biote.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BTMD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
